LYCOS RETRIEVER 
Meridian Bioscience
built 642 days ago
[W]hy does Meridian Bioscience continue to be a good investment? In short, the company continues to latch on to new opportunities. In early August, the company was awarded a five-year contract by the National Institutes of Health (NIH) to test and produce experimental viral vaccines. A few weeks later the company announced the start of phase 1 and 2 clinical trials for a vaccine aimed at preventing disease caused by parvovirus infections. These developments will help to shore up the company's life science business.
Source:
CINCINNATI--(BUSINESS WIRE)--August 14, 2007 Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today provided the financial community with guidance regarding the Company's fiscal 2008 sales and earnings estimates. Based on the Company's business planning and budgeting activities for the fiscal year ending September 30, 2008, management expects net sales to be in the range of $140 to $142 million and per share diluted earnings to be between $0.72 and $0.75. The per share estimates assume an increase in average shares outstanding from approximately 40.7 million at fiscal 2007 year end to 41 million at fiscal 2008 year end. Net income is expected to increase between 20% and 25% from fiscal 2007 to fiscal 2008. Importantly, this increase excludes the impact of tax benefits of $2.4 million, or $0.06 per diluted share, recognized in fiscal 2007 which are not expected to recur. The sales and earnings guidance provided in this press release is from expected internal growth and does not include the impact of any acquisitions the Company might complete during fiscal 2007 or 2008.
Source:
CINCINNATI -- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that the Board of Directors has appointed Jack Kraeutler to Chief Executive Officer. Mr. Kraeutler joined the Company in January, 1992 as Executive Vice President and Chief Operating Officer. In July 1992, Mr. Kraeutler was named President and Chief Operating Officer of Meridian. Before joining Meridian, Mr. Kraeutler served as Vice President, General Manager for a division of Carter-Wallace, Inc. Prior to that, he held key marketing and technical positions with Becton, Dickinson and Company and Organon, Inc. Mr. Kraeutler has more than 35 years of experience in the medical diagnostics industry and has been a Director of Meridian since 1997.
Source:
As Executive Vice President, Rick has executive responsibilities for the corporation, Meridian Bioscience, Inc. Rick ... holds the responsibility of President of the Meridian Life Science business unit. Rick has been with Meridian for ten years. Prior to Meridian, Rick held various Sales and Marketing positions with Abbott Diagnos-tics. Rick graduated with a MBA degree from Xavier University and an undergraduate degree in Biochemistry from Juniata College.
Source:
Meridian Bioscience gets FDA OK for Tru Flu, Tru RSV tests. Need a second Rock Band guitar Here is one way to get it. Pro Business Republican Lott To Retire From US Senate. Sarkozy urges calm after violence in Paris suburb. New York Fed Adds Extra Liquidity. Carson will not run for re election.
Source:
CINCINNATI--(BUSINESS WIRE)--April 12, 2006--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that it has executed a settlement agreement with Astra S.r.l. regarding Meridian's patented technology for detecting H. pylori, the primary cause of peptic ulcers. In the agreement, Astra acknowledges the existence, validity and scope of Meridian's patent, EPO 0806667. Astra further agrees to: 1) cease all promotion and distribution of its infringing products, and; 2) for any existing customers, to replace the Astra product with Meridian HpSA products(s).
Source:
MORE ABOUT
Meridian Bioscience